This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Ophthalmology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Koji Okada, MD; Douglas S. Gregory, PhD

Arch Ophthalmol. 2001;119:235-239.

Objective  To determine the effect of norepinephrine (NE) released from endogenous ocular stores on intraocular pressure (IOP) and aqueous flow in rabbits.

Methods  The IOP was measured with a pneumatonometer, the aqueous flow with a scanning fluorophotometer, and the aqueous NE by methylation with catechol-O-methyltransferase in the presence of S-adenosyl-L-[methyl-³H]methionine.

Results  Hydroxyamphetamine increased IOP in a dose-dependent fashion. Surgical removal of the superior cervical sympathetic ganglion eliminated the increase in IOP and pupil diameter; preganglionic section of the cervical sympathetic trunk did not. Hydroxyamphetamine increased the concentration of NE in the aqueous. Increased IOP was not accompanied by increased aqueous flow and was eliminated by blockade of ₁-adrenergic receptors but not - or ₂-adrenergic receptors.

Conclusions  Increased IOP after hydroxyamphetamine application is consistent with earlier suggestions that the nocturnal circadian increase in IOP in rabbits is mediated in part by NE released from ocular sympathetic nerves. However, failure of hydroxyamphetamine to increase aqueous flow and of -adrenergic blockade to blunt the increase in IOP does not support our suggestion that the nocturnal increase in IOP results in part from NE stimulation of ciliary process -adrenergic receptors and increased aqueous flow.

Clinical Relevance  In addition to increasing pupil diameter, hydroxyamphetamine increases IOP.

From the Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Conn. Dr Okada is now with the Department of Ophthalmology, Hiroshima University School of Medicine, Hiroshima, Japan. The authors have no finanical or proprietary interest in any of the drugs used in this study or in the companies that have supplied drugs.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?